Health Canada approved the first generic version of semaglutide on Tuesday, April 29, 2026 [2, 4].

The decision is significant because it introduces a lower-cost alternative to Ozempic, potentially reducing the financial burden on patients and the national healthcare system amid rising GLP-1 drug prices [5, 6].

The generic drug, manufactured by India-based Dr. Reddy's Laboratories [3, 7], is a once-a-week injectable treatment for adults with type 2 diabetes [1, 3]. This approval marks a milestone for the region, as Canada is the first G7 nation to approve a generic version of semaglutide [2, 8].

Health Canada said the approval will increase access and lower costs for patients [4]. The regulator said the availability of generic drugs is expected to have a positive impact in Canada, including potential cost savings for patients and the healthcare system [6].

While the medication is marketed under the brand name "Obeda" in India, the regulator has not specified a brand name for the Canadian market [9, 10]. The approval comes as competition among GLP-1 medications increases globally [4].

Officials from Health Canada said the move aims to broaden patient access to essential diabetes care. The transition to generic options typically follows the expiration of patents or through specific regulatory pathways that allow for bioequivalent alternatives to enter the market [5, 6].

“Canada is the first G7 nation to approve a generic version of semaglutide.”

This approval signals a shift in the accessibility of GLP-1 receptor agonists, which have seen surging demand for both diabetes and weight management. By becoming the first G7 country to permit a generic semaglutide, Canada is positioning itself to lower public health expenditures and reduce the reliance on high-cost brand-name pharmaceuticals from companies like Novo Nordisk.